lenvatinib and pembrolizumab in microsatellite stable crc
Published 3 years ago • 326 plays • Length 3:29Download video MP4
Download video MP3
Similar videos
-
1:08
first-line durvalumab monalizumab in microsatellite-stable crc
-
2:11
pembrolizumab vs. chemo in first-line mcrc
-
0:24
how can we incorporate checkpoint inhibition in microsatellite stable colorectal cancer?
-
6:56
prior rt may potentially enhance treatment of mss-crc with regorafenib and pembrolizumab
-
1:06
leap-011: first-line pembrolizumab plus lenvatinib for uc
-
6:49
lenvatinib plus pembrolizumab versus soc for previously treated metastatic colorectal cancer
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
2:08
clear: lenvatinib and pembrolizumab efficacy in arcc across baseline tumor sizes
-
2:03
pembrolizumab therapy for microsatellite instability-high colorectal cancer
-
1:28
keynote-b61: first-line lenvatinib pembrolizumab in non-clear cell rcc
-
3:28
keynote-775 subgroup analysis in advanced endometrial cancer
-
4:02
#esmo19: lenvatinib (len) and pembrolizumab (pembro) in advanced endometrial cancer
-
1:39
dr. makker on synergy between lenvatinib and pembrolizumab in endometrial cancer
-
0:52
dr. zamarin on lenvatinib plus pembrolizumab in endometrial cancer
-
5:14
lenvatinib plus pembrolizumab after progression on immune checkpoint inhibitors for metastatic rcc
-
2:56
keynote-177: final pfs analysis of pembrolizumab in patients with msi-h/dmmr mcrc
-
3:24
endometrial cancer health outcomes: pembrolizumab for patients with msi-high endometrial cancer
-
1:22
discussing the phase ii study of lenvatinib/pembrolizumab in metastatic ccrcc
-
7:05
health-related quality of life with lenvatinib plus pembrolizumab for patients with advanced rcc